 Competitor with similar mechanism of action drug resmetirom will release results from its phase 3 MAESTRO-NASH study in Q4 of 2022. Biopsy data is going to be key for success. Viking Therapeutics will release its results from the phase 2b VOYAGE study using VK2809 for NASH in the 1st half of 2023. 